Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 2:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 682 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Influenza a Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children

NCT00764790
View directory record Official record
Conditions
Influenza
Interventions
Fluarix, Fluzone
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 35 Months
Enrollment
3,317 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
62
States / cities
Birmingham, Alabama • Dothan, Alabama • Benton, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Sep 9, 2026, 2:15 AM EDT
Completed Phase 1 Interventional

PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC

NCT02544880
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Interventions
Tadalafil, Anti-MUC1 Vaccine, Anti-Influenza Vaccine, Tadalafil Placebo, Anti-MUC1 Vaccine Placebo, Standard of Care Treatment, Anti-Influenza Vaccine Placebo
Drug · Biological · Other
Lead sponsor
Donald T. Weed, MD, FACS
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Sep 9, 2026, 2:15 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults

NCT07111078
View directory record Official record
Conditions
Influenza Prevention, Pandemic Influenza Prevention
Interventions
VRC-FLUMOS0122-00-VP, ALFQ
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 9, 2026, 2:15 AM EDT
Completed Phase 3 Interventional Results available

Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older

NCT01992094
View directory record Official record
Conditions
Influenza
Interventions
QIVc, TIV1c, TIV2c
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
18 Years and older
Enrollment
2,680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
40
States / cities
Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Sep 9, 2026, 2:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Immunogenicity of a Live Attenuated Virus Vaccine for the Prevention of H2N3 Influenza

NCT01175122
View directory record Official record
Conditions
Influenza A Virus Infection
Interventions
H2N3 MO 2003/AA ca Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 42 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Sep 9, 2026, 2:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines

NCT02415842
View directory record Official record
Conditions
Immunologic Tests
Interventions
Serum samples
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 64 Years
Enrollment
414 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 9, 2026, 2:15 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older

NCT05608005
View directory record Official record
Conditions
Influenza, Healthy Volunteers
Interventions
Panblok + MF59 Dose 1, Panblok + MF59 Dose 2, Unadjuvanted Panblok Dose 3
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
581 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
16
States / cities
Mesa, Arizona • Hallandale, Florida • Hollywood, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Sep 9, 2026, 2:15 AM EDT
Completed No phase listed Observational

Novel Influenza A (H1N1) Surveillance Registry

NCT01046331
View directory record Official record
Conditions
Novel Influenza A, H1N1, Influenza
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
86
States / cities
Anchorage, Alaska • Phoenix, Arizona • Little Rock, Arkansas + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 9, 2026, 2:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Safety and Immunogenicity Study in Healthy Adults of VAX125, a Recombinant HA-flagellin Influenza Vaccine

NCT00730457
View directory record Official record
Conditions
Influenza
Interventions
VAX125
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Sep 9, 2026, 2:15 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)

NCT01773928
View directory record Official record
Conditions
Influenza
Interventions
Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified), VCIV manufactured with the current manufacturing process (VCIV current), Fluzone®, licensed trivalent influenza vaccine (TIV)
Biological
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,928 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
20
States / cities
Chandler, Arizona • Anaheim, California • Paramount, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 9, 2026, 2:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Fever After Simultaneous Versus Sequential Vaccination in Young Children

NCT03165981
View directory record Official record
Conditions
Fever After Vaccination, Fever, Febrile Seizure
Interventions
PCV13, DTaP, IIV
Biological
Lead sponsor
Duke University
Other
Eligibility
12 Months to 16 Months
Enrollment
221 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Oakland, California • Atlanta, Georgia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2024 · Synced Sep 9, 2026, 2:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

NCT01579916
View directory record Official record
Conditions
Influenza
Interventions
Trivalent Influenza Virus Vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
3
States / cities
Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 2, 2014 · Synced Sep 9, 2026, 2:15 AM EDT
Completed No phase listed Observational

Chart Review of Antivirals for Influenza in Infants

NCT00311701
View directory record Official record
Conditions
Influenza
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 11 Months
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
15
States / cities
Birmingham, Alabama • Pulaski, Arkansas • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 12, 2011 · Synced Sep 9, 2026, 2:15 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Increasing COVID-19, Influenza, and Pneumonia Vaccine Uptake

NCT04761692
View directory record Official record
Conditions
Covid19, Influenza, Pneumonia, Vaccine Refusal
Interventions
Full VEPMP Intervention, Partial VEPMP Intervention, Delayed VEPMP Intervention
Behavioral
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
65 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Sep 9, 2026, 2:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older

NCT06118151
View directory record Official record
Conditions
Influenza, Influenza Immunization
Interventions
Influenza Hemagglutinin mRNA vaccine, Quadrivalent Recombinant Influenza Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
388 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
20
States / cities
Rolling Hills Estates, California • San Diego, California • Coral Gables, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 9, 2026, 2:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant

NCT02957656
View directory record Official record
Conditions
Influenza A Virus, H7N9 Subtype
Interventions
H7N9 pLAIV, H7N9 pIIV, AS03 adjuvant
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
20 Years to 49 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2016
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Sep 9, 2026, 2:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Influenza Vaccine Responses as a Means of Assessing Immune Competence in Chimeric Kidney/Stem Cell Transplant Recipients

NCT02623075
View directory record Official record
Conditions
Influenza
Interventions
Influenza vaccine
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 9, 2026, 2:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents

NCT01609998
View directory record Official record
Conditions
Influenza
Interventions
Seasonal Influenza DNA vaccine, TIV
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 17 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
5
States / cities
Atlanta, Georgia • St Louis, Missouri • Lebanon, New Hampshire + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Sep 9, 2026, 2:15 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly

NCT03739112
View directory record Official record
Conditions
Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions
Quadrivalent VLP Vaccine, Fluarix Quadrivalent® Comparator Vaccine
Biological
Lead sponsor
Medicago
Industry
Eligibility
65 Years and older
Enrollment
12,794 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
50
States / cities
Mobile, Alabama • Tempe, Arizona • Banning, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Sep 9, 2026, 2:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection

NCT04164212
View directory record Official record
Conditions
Influenza
Interventions
Flumist Quadrivalent Nasal Product
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 49 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 9, 2026, 2:15 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults

NCT05091307
View directory record Official record
Conditions
COVID-19 Prevention
Interventions
Ad26.COV2.S, Placebo, Influenza Vaccine
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years and older
Enrollment
861 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
17
States / cities
Tempe, Arizona • San Diego, California • Coral Gables, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 9, 2026, 2:15 AM EDT
Completed Not applicable Interventional Results available

Patient Portal Flu Vaccine Reminders (RCT 6)

NCT06062264
View directory record Official record
Conditions
Influenza, Respiratory Tract Infections
Interventions
Portal-based Video Message, Portal-based Infographic Message
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
6 Months and older
Enrollment
22,233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2025 · Synced Sep 9, 2026, 2:15 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older

NCT06907511
View directory record Official record
Conditions
Pandemic Influenza Immunization, Healthy Volunteers
Interventions
Pandemic flu H5 HA mRNA SD2 vaccine, Placebo
Biological · Other
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
13
States / cities
La Mesa, California • DeLand, Florida • Lakeland, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 9, 2026, 2:15 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults

NCT03301051
View directory record Official record
Conditions
Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections, Influenza
Interventions
Quadrivalent VLP Vaccine, Placebo
Biological
Lead sponsor
Medicago
Industry
Eligibility
18 Years to 64 Years
Enrollment
10,160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
29
States / cities
Mobile, Alabama • Anaheim, California • Milford, Connecticut + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 9, 2026, 2:15 AM EDT